Reports Q1 revenue $21.9B, consensus $21.57B. “The power of Johnson & Johnson’s uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 guidance,” said Joaquin Duato, Chairman and CEO, Johnson & Johnson. “During the quarter, we fortified our position as an innovation powerhouse with major advancements across our pipeline, including TREMFYA in IBD, RYBREVANT plus LAZCLUZE in non-small-cell lung cancer, and OTTAVA, our soft tissue surgical robotic system, and further enhanced our leading neuroscience portfolio with the completion of the Intra-Cellular Therapies acquisition.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Notable companies reporting before tomorrow’s open
- Johnson & Johnson (JNJ) Stands Firm as Recession-Resistant Tariff-Proof Anchor
- Johnson & Johnson price target lowered to $162 from $165 at Raymond James
- Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke
- Options Volatility and Implied Earnings Moves This Week, April 14 – April 17, 2025